Background Lnc‐IRF2‐3 and Lnc‐ZNF667‐AS1 were recently studied as a positive biomarker for many tumor cells. However, experimental studies found that they are associated with worse outcomes in B‐CLL. Methods A prospective case study was conducted on 135 B‐CLL patients that were compared to thirty healthy controls. The patients were followed up for 40 months and quantitative measurements of Lnc‐IRF2‐3 and Lnc‐ZNF667‐AS1 were measured and compared between the two groups as well as high‐risk and low low‐risk B‐CLL. Results Lnc‐IRF2‐3 and Lnc‐ZNF667‐AS1 had a high specificity (94% and 85%) and sensitivity (85%, 87%), respectively, to differentiate B‐CLL from healthy controls. Furthermore, they showed high expression levels in high‐risk CLL groups. For survival analysis, there was a negative correlation between overall survival (OS) and progression‐free survival (PFS) and both biomarkers. However, it was not evident in multivariate Cox regression analysis; in patients with Lnc‐IRF2‐3 expression level, >67 had a significant decrease in OS and PFS. However, there is no significant effect for high expression levels of Lnc‐ZNF667‐AS1 on OS (P = .16) or PFS (P = .48). Conclusion The Lnc‐IRF2‐3 and Lnc‐ZNF667‐AS1 are promising prognostic biomarkers in B‐CLL.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.